← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab [TECENTRIQ])

Neoplasms · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 33.33%임상시험 4상태 ACTIVE
AntibodystaleEisai Inc.Phase 2

Farletuzumab ecteribulin (Farletuzumab ecteribulin)

Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+2
효능 ORR 20%임상시험 4상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Icrucumab (Icrucumab)

Colon Cancer; Rectal Cancer · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+4
효능 ORR 28.8%임상시험 4상태 ACTIVE
AntibodystaleAstraZenecaPhase 3

MEDI4736+Tremelimumab (MEDI4736+Tremelimumab)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase3#항체#면역항체+2
효능 ORR 37.4%임상시험 4상태 ACTIVE
AntibodystaleBiogenPhase 2

Natalizumab (Natalizumab)

Crohn's Disease · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Phase2#항체#면역항체+3
효능 ORR 52%임상시험 4상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, SD-101 + Pembrolizumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 3.2%임상시험 4상태 RECRUITING
AntibodystaleBeiGenePhase 1

atezolizumab (Tecentriq, Tislelizumab，atezolizumab or sugemalimab)

NSCLC · NSCLC

#NSCLC#Antibody#Phase1#항체#면역항체+2
임상시험 4상태 RECRUITING
AntibodystaleRegeneronPhase 2

VV1 + Cemiplimab (VV1 + Cemiplimab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
AntibodystalePeregrine PharmaceuticalsPhase 2

bavituximab (bavituximab)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 9%임상시험 4상태 ACTIVE
AntibodyBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab)

Liver Cancer; Antibody · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab)

Hepatic Cancer; Surgery · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+4
임상시험 4상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 ACTIVE
AntibodystaleDeutsches Herzzentrum MuenchenApproved

Abciximab (Abciximab)

Acute Myocardial Infarction · Myocardial Infarction

#MyocardialInfarction#Antibody#Approved#항체#면역항체+3
임상시험 3상태 ACTIVE
AntibodystaleAbbVieApproved

ADA (Adalimumab, Adalimumab (ADA))

Rheumatoid Arthritis · Uveitis

#Uveitis#Antibody#Approved#항체#면역항체+3
효능 ORR 3.6%임상시험 3상태 ACTIVE
AntibodyAbbVieApproved

adalimumab (Humira, Adalimumab Dose Intensification)

Crohn Disease (CD) · Crohn Disease (CD)

#CrohnDiseaseCD#Antibody#Approved#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodyThe First Affiliated Hospital o…Phase 2

Adebellizumab (Adebellizumab)

Resectable Lung Non-Small Cell Carcinoma · Resectable Lung Non-Small Cell Carcinoma

#ResectableLungNon-SmallCellCarci#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleGilead SciencesPhase 1

Andecaliximab (Andecaliximab)

Gastric Adenocarcinoma · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase1#항체#면역항체+3
효능 ORR 9.7%임상시험 3상태 DISCONTINUED
AntibodyUniversity of CalgaryApproved

Anti-IL12/23 or anti-IL23 - Risankizumab (Anti-IL12/23 or anti-IL23 - Risankizumab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Approved#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody)

Breast Neoplasms · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+3
효능 ORR 20%임상시험 3상태 ACTIVE

16 / 92 페이지

← 이전다음 →